

**LISTING OF CLAIMS:**

Claim 1. (Original) A process for the production of  $\alpha$ -interferon comprising the steps:

- i) inducing of human leukocytes by means of a virus,
- ii) treating the leukocytes with an enhancing agent selected from
  - a) xanthine, pyrimidinol and pyrimidinone, theophylline, theobromine, enprophylline, hypoxanthine, 8-phenyltheophylline, 2-amino-5-bromo-6-methylpyrimidinol, 2-amino-6-methyl-4-pyrimidinol and thymine;
  - b) an organic solvent selected from the group consisting of non-aromatic ketones, aliphatic or cyclic amides, alkylated aliphatic or cyclic urea derivatives and aliphatic or cyclic sulfoxides; or a combination of the compounds from a) with an organic solvent from b).

<sup>10</sup>  
Claim ~~2~~. (Original) A process according to claim 1, characterized in that the leukocytes are monocytes.

<sup>7</sup>  
Claim ~~3~~. (Previously Presented) A process according to claim 1, characterized in that the enhancing agent is added at the same time or up to 4 hours after the virus induction.

<sup>2</sup>  
Claim ~~4~~. (Previously Presented) A process according to claim 1, characterized in that the virus is Sendai virus.

4

Claim ~~5~~. (Previously Presented) A process according to claim 1, characterized in that the enhancing agent is theophylline.

Claim 6. (Withdrawn) A process according to claim 1, characterized in that the enhancing agent is 2-amino-5-bromo-6-methyl-4-pyrimidinol.

Claim 7. (Withdrawn) A process according to claim 1, characterized in that the enhancing agent is thymine.

5

Claim ~~8~~. (Currently Amended) A process according to claim 1, characterized in that the organic solvent is any of acetone, 2-butanone, 1,3-dimethyl-2-imidazolidinone, dimethylsulfoxide, N-ethyl-2-pyrrolidinone, 4-methyl-2-pentanone, N-methyl-2-pyrrolidinone, 2-pyrrolidinone, tetramethylene sulfoxide or and N,N-dimethylacetamide.

6

Claim ~~9~~. (Original) A process according to claim ~~8~~, characterized in that the solvent is N-methyl-2-pyrrolidinone.

5

11

Claim ~~10~~. (Previously Presented) A process according to claim ~~2~~, characterized in that the enhancing agent is added at the same time or up to 4 hours after the virus induction.

10

<sup>13</sup>  
Claim ~~11~~. (Previously Presented) A process according to claim <sup>12</sup>~~2~~,  
characterized in that the virus is Sendai virus.

<sup>8</sup>  
Claim ~~12~~. (Previously Presented) A process according to claim <sup>7</sup>~~2~~,  
characterized in that the virus is Sendai virus.

<sup>12</sup>  
Claim ~~13~~. (Previously Presented) A process according to claim <sup>11</sup>~~10~~,  
characterized in that the virus is Sendai virus.

<sup>10</sup>  
Claim 14. (Previously Presented) A process according to claim ~~2~~,  
characterized in that the enhancing agent is theophylline.

<sup>9</sup>  
Claim ~~15~~. (Previously Presented) A process according to claim <sup>7</sup>~~2~~,  
characterized in that the enhancing agent is theophylline.

<sup>3</sup>  
Claim ~~16~~. (Previously Presented) A process according to claim <sup>2</sup>~~4~~,  
characterized in that the enhancing agent is theophylline.

Claim 17. (Withdrawn) A process according to claim 2, characterized in  
that the enhancing agent is 2-amino-5-bromo-6-methyl-4-pyrimidinol.

Claim 18. (Withdrawn) A process according to claim 3, characterized in  
that the enhancing agent is 2-amino-5-bromo-6-methyl-4-pyrimidinol.

Claim 19. (Withdrawn) A process according to claim 2, characterized in that the enhancing agent is thymine.

<sup>15</sup>  
Claim ~~20~~. (Currently Amended) A process according to claim <sup>20</sup>~~2~~, characterized in that the organic solvent is any of acetone, 2-butanone, 1,3-dimethyl-2-imidazolidinone, dimethylsulfoxide, N-ethyl-2-pyrrolidinone, 4-methyl-2-pentanone, N-methyl-2-pyrrolidinone, 2-pyrrolidinone, tetramethylene sulfoxide or and N,N-dimethylacetamide.